Pre-exposure prophylaxis for HIV prevention during pregnancy and lactation: forget not the women and children

Lisa Horgan, Christopher C. Blyth, Asha C. Bowen, David A. Nolan, Andrew P. McLean-Tooke

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Pregnancy is known to be a time of increased susceptibility to acquiring to human immunodeficiency virus (HIV) infection and this increased maternal risk places the unborn child at risk of vertical transmission. Pre-exposure prophylaxis (PrEP) involves the provision of antiretroviral therapy to an HIV-negative individual with ongoing risk of HIV exposure to limit the likelihood of HIV transmission. The inclusion of PrEP as part of a comprehensive strategy is recognised as an effective and safe means of reducing HIV infection in serodiscordant couples, thereby reducing the risk of vertical transmission of HIV. Current data suggest that PrEP is safe to continue during pregnancy and breastfeeding in HIV-negative women who remain vulnerable to acquiring HIV. The recent Pharmaceutical Benefits Scheme subsidisation of PrEP has reduced the financial and practical obstacles of PrEP provision, and a subsequent increase in patient awareness and acceptance of PrEP is expected. The framework for appropriately identifying and managing at-risk pregnant and lactating women requiring PrEP is poorly defined and warrants further clarification to better support clinicians and this patient group. This review discusses the current recommendations highlighting the gaps in the guidelines and makes some recommendations for future guideline development.

Original languageEnglish
Pages (from-to)281-284
Number of pages4
JournalMedical Journal of Australia
Volume210
Issue number6
DOIs
Publication statusPublished - Apr 2019

Cite this

@article{f07762f1337049f9ab12654585dc2e53,
title = "Pre-exposure prophylaxis for HIV prevention during pregnancy and lactation: forget not the women and children",
abstract = "Pregnancy is known to be a time of increased susceptibility to acquiring to human immunodeficiency virus (HIV) infection and this increased maternal risk places the unborn child at risk of vertical transmission. Pre-exposure prophylaxis (PrEP) involves the provision of antiretroviral therapy to an HIV-negative individual with ongoing risk of HIV exposure to limit the likelihood of HIV transmission. The inclusion of PrEP as part of a comprehensive strategy is recognised as an effective and safe means of reducing HIV infection in serodiscordant couples, thereby reducing the risk of vertical transmission of HIV. Current data suggest that PrEP is safe to continue during pregnancy and breastfeeding in HIV-negative women who remain vulnerable to acquiring HIV. The recent Pharmaceutical Benefits Scheme subsidisation of PrEP has reduced the financial and practical obstacles of PrEP provision, and a subsequent increase in patient awareness and acceptance of PrEP is expected. The framework for appropriately identifying and managing at-risk pregnant and lactating women requiring PrEP is poorly defined and warrants further clarification to better support clinicians and this patient group. This review discusses the current recommendations highlighting the gaps in the guidelines and makes some recommendations for future guideline development.",
keywords = "Pregnancy, Breastfeeding, Immunology, Infectious diseases, Prescribing, Immunologic deficiency syndromes, Obstetrics, Acquired immunodeficiency syndrome, TENOFOVIR DISOPROXIL FUMARATE, INFECTION, TRANSMISSION, IMMUNITY, MEN, SEX",
author = "Lisa Horgan and Blyth, {Christopher C.} and Bowen, {Asha C.} and Nolan, {David A.} and McLean-Tooke, {Andrew P.}",
year = "2019",
month = "4",
doi = "10.5694/mja2.50052",
language = "English",
volume = "210",
pages = "281--284",
journal = "Medical Journal Australia",
issn = "0025-729X",
publisher = "Australasian Medical Publishing Co. Ltd",
number = "6",

}

Pre-exposure prophylaxis for HIV prevention during pregnancy and lactation : forget not the women and children. / Horgan, Lisa; Blyth, Christopher C.; Bowen, Asha C.; Nolan, David A.; McLean-Tooke, Andrew P.

In: Medical Journal of Australia, Vol. 210, No. 6, 04.2019, p. 281-284.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Pre-exposure prophylaxis for HIV prevention during pregnancy and lactation

T2 - forget not the women and children

AU - Horgan, Lisa

AU - Blyth, Christopher C.

AU - Bowen, Asha C.

AU - Nolan, David A.

AU - McLean-Tooke, Andrew P.

PY - 2019/4

Y1 - 2019/4

N2 - Pregnancy is known to be a time of increased susceptibility to acquiring to human immunodeficiency virus (HIV) infection and this increased maternal risk places the unborn child at risk of vertical transmission. Pre-exposure prophylaxis (PrEP) involves the provision of antiretroviral therapy to an HIV-negative individual with ongoing risk of HIV exposure to limit the likelihood of HIV transmission. The inclusion of PrEP as part of a comprehensive strategy is recognised as an effective and safe means of reducing HIV infection in serodiscordant couples, thereby reducing the risk of vertical transmission of HIV. Current data suggest that PrEP is safe to continue during pregnancy and breastfeeding in HIV-negative women who remain vulnerable to acquiring HIV. The recent Pharmaceutical Benefits Scheme subsidisation of PrEP has reduced the financial and practical obstacles of PrEP provision, and a subsequent increase in patient awareness and acceptance of PrEP is expected. The framework for appropriately identifying and managing at-risk pregnant and lactating women requiring PrEP is poorly defined and warrants further clarification to better support clinicians and this patient group. This review discusses the current recommendations highlighting the gaps in the guidelines and makes some recommendations for future guideline development.

AB - Pregnancy is known to be a time of increased susceptibility to acquiring to human immunodeficiency virus (HIV) infection and this increased maternal risk places the unborn child at risk of vertical transmission. Pre-exposure prophylaxis (PrEP) involves the provision of antiretroviral therapy to an HIV-negative individual with ongoing risk of HIV exposure to limit the likelihood of HIV transmission. The inclusion of PrEP as part of a comprehensive strategy is recognised as an effective and safe means of reducing HIV infection in serodiscordant couples, thereby reducing the risk of vertical transmission of HIV. Current data suggest that PrEP is safe to continue during pregnancy and breastfeeding in HIV-negative women who remain vulnerable to acquiring HIV. The recent Pharmaceutical Benefits Scheme subsidisation of PrEP has reduced the financial and practical obstacles of PrEP provision, and a subsequent increase in patient awareness and acceptance of PrEP is expected. The framework for appropriately identifying and managing at-risk pregnant and lactating women requiring PrEP is poorly defined and warrants further clarification to better support clinicians and this patient group. This review discusses the current recommendations highlighting the gaps in the guidelines and makes some recommendations for future guideline development.

KW - Pregnancy

KW - Breastfeeding

KW - Immunology

KW - Infectious diseases

KW - Prescribing

KW - Immunologic deficiency syndromes

KW - Obstetrics

KW - Acquired immunodeficiency syndrome

KW - TENOFOVIR DISOPROXIL FUMARATE

KW - INFECTION

KW - TRANSMISSION

KW - IMMUNITY

KW - MEN

KW - SEX

U2 - 10.5694/mja2.50052

DO - 10.5694/mja2.50052

M3 - Review article

VL - 210

SP - 281

EP - 284

JO - Medical Journal Australia

JF - Medical Journal Australia

SN - 0025-729X

IS - 6

ER -